levofloxacin has been researched along with cyclosporine in 25 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (cyclosporine) | Trials (cyclosporine) | Recent Studies (post-2010) (cyclosporine) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 377 | 2 | 170 |
| 4,346 | 581 | 2,209 | 30,547 | 3,802 | 6,558 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inui, KI; Ito, T; Tanaka, K; Yano, I | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chien, SC; Doose, DR; Nayak, RK; Walker, SA; Williams, RR | 1 |
| Hashimoto, Y; Inui, K; Ito, T; Matsuo, Y; Yano, I | 1 |
| Hashimoto, Y; Inui, KI; Yamaguchi, H; Yano, I | 1 |
| Inui, K; Saito, H; Yamaguchi, H; Yano, I | 2 |
| Borrás-Blasco, J; Conesa-García, V; Gomez-Corrons, A; González-Delgado, M; Marín-Jiménez, F; Navarro-Ruiz, A | 1 |
| Basile, V; Capone, D; Carrano, R; Federico, S; Gentile, A; Palmiero, G | 1 |
| Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yu, KS | 1 |
| Bielory, L; Kumar, S; Syed, BA | 1 |
| Kishimoto, K; Matsuse, H; Nakayama, H; Oshio, T | 1 |
| Chauhan, A; Dixon, P | 1 |
| Han, G; Hawkins, BS; Kuo, IC; Leslie, L; Liu, SH; Ng, SM; Ren, M | 1 |
4 review(s) available for levofloxacin and cyclosporine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current options and emerging therapies for anterior ocular inflammatory disease.
Topics: Anti-Infective Agents; Antibodies, Monoclonal; Chemokine CCL11; Clinical Trials as Topic; Conjunctivitis, Allergic; Cyclosporine; Dibenzoxepins; Dry Eye Syndromes; Fluoroquinolones; Histamine H1 Antagonists; Humans; Immunotherapy; Levofloxacin; Moxifloxacin; Olopatadine Hydrochloride; Uveitis, Anterior | 2014 |
Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Conjunctivitis; Conjunctivitis, Viral; Cyclosporine; Dexamethasone; Female; Fluorometholone; Ganciclovir; Humans; Keratoconjunctivitis; Levofloxacin; Lubricant Eye Drops; Male; Middle Aged; Povidone-Iodine; Tacrolimus; Trifluridine; Young Adult | 2022 |
2 trial(s) available for levofloxacin and cyclosporine
| Article | Year |
|---|---|
Levofloxacin does not alter cyclosporine disposition.
Topics: Adult; Cross-Over Studies; Cyclosporine; Double-Blind Method; Drug Interactions; Female; Humans; Immunosuppressive Agents; Levofloxacin; Male; Ofloxacin | 1998 |
Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Cyclosporine; Dose-Response Relationship, Drug; Half-Life; Humans; Immunosuppressive Agents; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Tandem Mass Spectrometry; Young Adult | 2012 |
19 other study(ies) available for levofloxacin and cyclosporine
| Article | Year |
|---|---|
Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
Topics: Animals; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Daunorubicin; Epithelial Cells; Epithelium; Fluoroquinolones; Humans; Kidney; Levofloxacin; LLC-PK1 Cells; Ofloxacin; Quinolones; Swine | 1997 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1.
Topics: 4-Chloromercuribenzenesulfonate; Animals; Anti-Infective Agents; Cyclosporine; Epithelial Cells; Fluoroquinolones; Hydrogen-Ion Concentration; Kidney; Levofloxacin; LLC-PK1 Cells; Ofloxacin; Piperazines; Quinolones; Swine | 1998 |
Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Topics: Anti-Infective Agents; Biological Transport; Caco-2 Cells; Cyclosporine; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Intestinal Mucosa; Levofloxacin; Metabolic Clearance Rate; Ofloxacin; Piperazines | 2000 |
Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Topics: Adenosine Triphosphate; Anti-Infective Agents; Biological Transport; Caco-2 Cells; Carbon Radioisotopes; Chlorides; Cyclosporine; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Mucosa; Levofloxacin; Ofloxacin; Piperazines | 2001 |
Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Topics: Animals; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biological Availability; Cyclosporine; Enzyme Inhibitors; Fluoroquinolones; Genes, MDR; Intestinal Mucosa; Kidney; Levofloxacin; Liver; Male; Mice; Mice, Knockout; Ofloxacin; Piperazines; Rats; Tissue Distribution | 2002 |
Ciprofloxacin, but not levofloxacin, affects cyclosporine blood levels in a patient with pure red blood cell aplasia.
Topics: Adult; Ciprofloxacin; Cyclosporine; Humans; Levofloxacin; Male; Ofloxacin; Red-Cell Aplasia, Pure | 2005 |
Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Clinical Trials as Topic; Cyclosporine; Drug Interactions; Female; Graft Rejection; Half-Life; Humans; Immunosuppressive Agents; Kidney Transplantation; Levofloxacin; Male; Ofloxacin; Tacrolimus; Transplantation Immunology | 2006 |
[A CASE OF PULMONARY MYCOBACTERIUM ABSCESSUS INFECTION THAT DEVELOPED DURING IMMUNOSUPPRESSIVE THERAPY FOR MYASTHENIA GRAVIS WITH RECURRENT THYMOMA].
Topics: Anti-Bacterial Agents; beta-Lactams; Clarithromycin; Cyclosporine; Drug Therapy, Combination; Glucocorticoids; Humans; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Male; Middle Aged; Myasthenia Gravis; Mycobacterium Infections, Nontuberculous; Neoplasm Recurrence, Local; Thymoma; Thymus Neoplasms; Treatment Outcome | 2016 |
Effect of the surface layer on drug release from delefilcon-A (Dailies Total1
Topics: Contact Lenses; Cyclosporine; Dexamethasone; Drug Delivery Systems; Drug Liberation; Levofloxacin; Timolol | 2017 |